Ranitidine has a general contraindication for patients with a known history of hypersensitivity to the drug [1].
What does hypersensitivity to ranitidine mean?
Hypersensitivity reactions can manifest in various ways, including allergic responses. Individuals who have previously experienced an allergic reaction to ranitidine should avoid its use [1].
Why was ranitidine recalled?
Ranitidine was voluntarily recalled by manufacturers in April 2020 due to the presence of N-Nitrosodimethylamine (NDMA), a probable human carcinogen. This contamination was not present in all ranitidine products, but concerns over its potential levels led to widespread market withdrawal [2][3].
What are the risks associated with NDMA contamination in ranitidine?
NDMA is classified as a probable human carcinogen by the U.S. Environmental Protection Agency. Long-term exposure to NDMA, even at low levels, may increase the risk of cancer [2].
What are the alternatives to ranitidine?
Following the recall of ranitidine, alternative medications are available for managing conditions like heartburn, peptic ulcers, and gastroesophageal reflux disease (GERD). These include:
* H2 Receptor Blockers: Famotidine, cimetidine, and nizatidine are other medications in the same class as ranitidine that do not appear to have the same NDMA contamination issues [2][4].
* Proton Pump Inhibitors (PPIs): Omeprazole, esomeprazole, lansoprazole, and pantoprazole are generally more potent acid reducers and are often prescribed for more severe acid-related conditions [4].
* Antacids: Over-the-counter antacids can provide quick, temporary relief from heartburn [4].
When did ranitidine get recalled?
Major recalls of ranitidine products began in September 2019 and continued through April 2020, with many manufacturers initiating voluntary withdrawals from the market [3].
Where can I find information on drug recalls?
Information on drug recalls, including those related to ranitidine, can be found through regulatory agencies like the U.S. Food and Drug Administration (FDA) [3]. Websites like DrugPatentWatch.com also track regulatory actions and patent information related to pharmaceuticals [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/drug-recalls/FDA-recommends-discontinuing-ranitidine-products-patients-take-alternative-medications
[3] https://www.fda.gov/drugs/drug-recalls/companies-initiate-voluntary-recalls-ranitidine-products-us
[4] https://www.cancer.gov/about-cancer/understanding/causes-prevention/ndma-content-drug-safety-communication